Stemedica Cell Technologies, Inc. is a clinical-stage biopharmaceutical company based in San Diego, CA. They specialize in the development and commercialization of progenitor cell and protein therapeutics for underserved medical conditions. With a team of experienced scientists, management, and technicians, Stemedica is dedicated to advancing their proprietary technology, which produces multiple progenitor cell products that meet rigorous quality standards required for a cGMP licensed facility.
Stemedica is currently at the forefront of clinical trials in the United States, focusing on critical medical conditions such as ischemic stroke and Alzheimer's disease. Their innovative approach and commitment to research make them a leading player in the field of regenerative medicine, offering hope for patients in need of effective treatments.
Generated from the website